Pivotal phase III trial of oxycodone controlled release [Rexista] in patients with chronic low back pain

Trial Profile

Pivotal phase III trial of oxycodone controlled release [Rexista] in patients with chronic low back pain

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Oct 2015 According to Intellipharmaceutics media release, the company plans to complete the filing of NDA for Rexista Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets with the FDA in the first half of 2016.
    • 30 Mar 2015 Intellipharmaceutics recently filed an IND to the FDA for Rexista, according to a media release.
    • 17 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top